Design Therapeutics, Inc. (DSGN)

NASDAQ • Healthcare

$10.24

-$0.25 (-2.4%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$10.42

Previous Close$10.24

Day Range$10.1 - $10.42

Avg. Volume (3M)523.8K

Market Cap$640.8M

52 Week Range

$5.73$17.25

Next EarningsIn 10 daysNov 4, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

Net Income (TTM)

-$70.7M

EPS (TTM)

-$1.18

ROA (TTM)

-32.91%

Current Ratio

18.86

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-6.3%Q3 2025-$0.34

+11.8%Q4 2025-$0.3

+28.9%Q1 2026-$0.27

+19.4%Q2 2026-$0.29

+7.1%Q3 2026-$0.32

Nov 4

in 10 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +7.1%

Design Therapeutics’ EPS topped expectations in the second fiscal quarter of 2026, based on preliminary results reported August 3, 2026, with EPS of -$0.32 topping the -$0.34 estimate by $0.02 as the early-stage biotech continued investing in its GeneTAC platform. Net income came in at about -$20.2 million, down ~6% year over year from roughly -$19.1 million a year ago, while operating income was about -$22.2 million. The company generated negative operating cash flow of roughly -$15.5 million during the quarter. For the next period, consensus calls for EPS of -$0.38.

Next report — what to expect

Design Therapeutics, Inc. (DSGN) is set to report earnings on November 4, 2026. Wall Street’s consensus calls for EPS of -$0.38, with recent history showing the company has beaten EPS estimates in 6 of its 8 most recent quarters. Focus will be on the EPS result relative to that benchmark.

View full earnings history

About Design Therapeutics, Inc.

Design Therapeutics, Inc. is a NASDAQ-listed biotechnology company developing medicines for genetic disorders rooted in nucleotide repeat expansions. In qualitative terms, it is an early-stage biotech business. The company centers its work on GeneTAC, a product candidate platform aimed at monogenic conditions caused by these repeat-driven defects.

Name

Design Therapeutics, Inc.

CEO

Pratik Shah

Website

www.designtx.com

Industry

Healthcare

Year Founded

2017

Employees

Today's Snapshot

AI-generated

DSGN closed 2.4% lower at 10.24, in line with a weaker sector. Volume was about two-fifths of its usual level. DSGN is due to report earnings on 4 November.

Trading Volume

Below 10d avg (518.4K)

206.9K

vs S&P 500 Today

Underperforming Market

-1.86%

Updated: October 23, 2026 at 20:11 UTC

Technical Indicators

0 Buy3 Neutral5 Sell

DSGN shows a decisively negative technical setup with the stock around $10.24 and a downward bias reinforced by trend and volume. ADX near the high 20s signals a developing directional trend while price trades beneath short- and longer-term moving averages, indicating that sellers retain control. Momentum readings are soft—RSI in the mid-30s and MACD slightly negative—while ATR is elevated as a percentage, implying larger intraday swings. OBV is materially negative, and the classic pivot lies above the current price, underscoring resistance. Technical takeaway: Strong Sell — downward bias persists with distribution.

All signals